首页>
外国专利>
Identifying the preferential target antigens of antitumor T cells comprises transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens
Identifying the preferential target antigens of antitumor T cells comprises transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens
展开▼
机译:鉴定抗肿瘤T细胞的优先靶抗原包括用编码肿瘤相关抗原的mRNA选择转染自体树突状或B细胞
展开▼
页面导航
摘要
著录项
相似文献
摘要
Identifying the preferential target antigens of antitumor T cells comprises isolating T cells from the blood of a tumor patient, transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens, contacting the T cells with the dendritic or B cells, and identifying the antigens recognized by the T cells. Independent claims are also included for: (1) identifying a tumor in a patient on the basis of an antigen expression pattern determined as above; (2) producing an individualized antitumor vaccine by identifying tumor-associated antigens as above and formulating the antigens as a vaccine; (3) treating a tumor disease on the basis of an antigen expression pattern determined as above. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Vaccine.
展开▼